Medtronic has commenced an IN.PACT BTK clinical study of IN.PACT 0.014 paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheter to treat patients with below-the-knee (BTK) peripheral arterial disease (PAD).

The study will evaluate the effectiveness of using a drug-coated balloon (DCB) in PAD treatment. IN.PACT 0.014 paclitaxel-coated PTA balloon catheter is an investigational device equipped with the firm's IN.PACT Admiral drug coating technology.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The prospective, randomised, multi-centre study will assess the catheter in up to 60 patients at four sites in Europe. The first patient was enrolled at Maria Cecilia Hospital in Cotignola, Italy.

Results from a preclinical study showed use of IN.PACT Admiral DCB in the superficial femoral arteries did not delay wound healing, despite measureable concentrations of paclitaxel in the adjacent cutaneous tissue.

"With these prior analyses, we have developed an unmatched knowledge around the treatment of below-the-knee disease and critical limb ischemia (CLI)."

Medtronic Peripheral's business vice-president and general manager Mark Pacyna said: "PAD below-the-knee is complex. With these prior analyses, we have developed an unmatched knowledge around the treatment of below-the-knee disease and critical limb ischemia (CLI).

See Also:

"Together with our clinical investigators, we look forward to launching the IN.PACT BTK study to evaluate the effect of the IN.PACT 0.014 in patients with below-the-knee PAD."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The primary endpoint of the studies was late lumen loss at nine months, in patients who were treated with the IN.PACT 0.014 DCB, when compared to standard PTA.

A wound care protocol is also included in the study to provide additional safety controls and ensure both routine and standard monitoring of patients by qualified professionals.